

Future Vaccine Manufacturing Research Hub

Technologies for Vaccine Delivery and Thermostabilisation

Dr Rongjun Chen & Jason Hallett
Chemical Engineering, Imperial College

rongjun.chen@imperial.ac.uk

j.hallett@imperial.ac.uk

Key challenges and opportunities

- **Delivery challenge**

- ✓ Degradability of biological vaccine antigens, e.g. nucleic acids, recombinant proteins
- ✓ To be delivered in the correct conformation
- ✓ Lacks potential to target the immune cells

- **Manufacturing and storage challenge**

- ✓ Reduced potency due to elevated temperature or accidental freezing
- ✓ Vaccine stability during storage

- **Opportunities**

- ✓ Targeted, efficient vaccine delivery formulations
- ✓ Manufacturable, heat-stable formulations


Proposed approaches and outcomes

- **Novel vaccine delivery formulations**
 - ✓ Bioresponsive polymers
 - ✓ Virus-like liposomes
- **Biostabilisation of vaccine delivery formulations**
 - ✓ Dry storage at room temperature
 - ✓ Sugar (trehalose, sucrose, glucose) loading by polymers/liposomes
- **Potential outcomes**
 - ✓ Flexible and robust platforms for improved stability and efficacy of vaccines
 - ✓ Manufacturable formulations with optimised biostabilisation during storage




Proposed approaches and outcomes 1

- **Novel vaccine delivery formulations**
 - ✓ Bioresponsive polymers
 - ✓ Virus-like liposomes
- **Biostabilisation of vaccine delivery formulations**
 - ✓ Dry storage at room temperature
 - ✓ Sugar (trehalose, sucrose, glucose) loading by polymers/liposomes
- **Potential outcomes**
 - ✓ Flexible and robust platforms for improved stability and efficacy of vaccines
 - ✓ Manufacturable formulations with optimised biostabilisation during storage

Inspiration from reproductive cycle of influenza virus





LIFE: THE SCIENCE OF BIOLOGY, Seventh Edition, Figure 13.4 The Reproductive Cycle of the Influenza Virus (Part I)
© 2004 Sinauer Associates, Inc. and W. H. Freeman & Co.





LIFE: THE SCIENCE OF BIOLOGY, Seventh Edition, Figure 13.4 The Reproductive Cycle of the Influenza Virus (Part II)
© 2004 Sinauer Associates, Inc. and W. H. Freeman & Co.


Viral peptide-mimicking, pH-responsive, pseudopeptides as delivery vehicles



Delivery through
vesicular/cellular membranes





Delivery to cell spheroids




Langendorff-perfused hearts perfused for 1 h at pH 7 followed by perfusion with fresh solution at pH 7.4

Delivery to organs

Virus-like nanoparticles as delivery vehicles



Intracellular delivery of biological molecules



Bim




scrBim




Intracellular delivery of biological molecules


Protein delivery



Delivery of peptide
PS-16-FITC (2 kDa)




Delivery of antibody
FITC-IgG (160 kDa)




Delivery of peptide CamBP (3.5 kDa)


RNA delivery




Cytoplasmic **siRNA**
delivery



Negative Control



Knockdown of **stathmin**
via siRNA delivery




Khormaei et al, *Advanced Functional Materials* 2013, 23, 565

Key challenges and opportunities 2

- **Delivery challenge**
 - ✓ Degradability of biological vaccine antigens, e.g. nucleic acids, recombinant proteins
 - ✓ To be delivered in the correct conformation
 - ✓ Lacks potential to target the immune cells
- **Manufacturing and storage challenge**
 - ✓ Reduced potency due to elevated temperature or accidental freezing
 - ✓ Vaccine stability during storage
- **Opportunities**
 - ✓ Targeted, efficient vaccine delivery formulations
 - ✓ **Manufacturable, heat-stable formulations**

Cold Chain

- Temperature-induced risk factors for vaccines:
 - Aggregation
 - Degradation/inactivation
- Costs vaccine programmes
\$200 - 300 million per year
- **Up to 80 %** of the cost of vaccination programmes





Inspiration from anhydrobiotic organisms




Dehydration
Freezing



Rehydration
Thawing




- Trehalose: non-toxic disaccharide
- Protection in freezing and drying
- Antioxidant




Heat-stable formulations (nanoparticle- & cell-based)





Trehalose loading into cells



Trehalose loading into virus-mimicking liposomes




Freeze drying of red blood cells




Prevention of haemoglobin oxidation in dried storage

Cytotoxicity, immunogenicity and tolerability profiles

Cell cytotoxicity




Immunogenicity



Weight change post injection (iv)




CD1-nude mice




Current and Future Strategies

- Use of biocompatible molten salts
- Modifying therapeutic proteins, VLPs and saRNA to be dissolved in biocompatible ionic liquids



- Imparts higher stability to proteins (50-70 C vs native; > 100 vs aqueous)
- Demonstrated for structural proteins (stable to 180 C), enzymes (activity increased 100-1000x), antibodies (30-50x longer stability; 46% binding retained), viruses (new materials applications)
- Thermal stability increased; aggregation effectively prevented; water excluded
- Needs biocompatibility, reversibility, combination with delivery vectors
- Potential alternative to freeze drying?



Similar principles apply to viruses, VLP and recombinant proteins

Research Objectives

STAGE 1
Monoclonal
Antibodies


STAGE 2
Viruses

STAGE 3
Vaccines

- Improve thermal stability of antibodies to **60 ° C** for **6 months** in ionic liquids
- Retain bioavailability depending on thermal stability and if reconstitution is needed
- Achieve similar results with viruses and vaccines

Exemplar target: Antibody Structure

- The Fc domain is constant in A.A and glycosylated for biological recognition
- Variable regions containing three antigen-binding loops each
- Variable region different in A.A sequence to maintain specificity




Monomer Y-shaped structure of antibodies, where V and C represents the variable and constant region. Subscripts L and H represent the light and heavy chains.¹

1. Perchiacca, J.M. and P.M. Tessier, *Annual Review of Chemical and Biomolecular Engineering*, 2012

Exemplar target: Virus Structure

- Viruses are intracellular parasites containing either RNA or DNA
- Genetic material encapsulated by a protein capsid
- VLPs a potential delivery mechanism





Different Viral Structures¹

1. Campbell, N.A., *Pearson Education Inc.*, 2008

Proteins in Ionic Liquids


- Proteins are poorly soluble in neat ionic liquids
- Adding polymer–surfactant to the protein surface produces liquid proteins
- **Retains biological activity** of proteins, enzymes and viruses
- Modified myoglobin and glucosidase dissolved in hydrophilic and hydrophobic ionic liquids
- Increased protein denaturation temperature by **60° C** to **140° C** compared to aqueous solution




Modified proteins to allow dissolution in ionic liquids^{1,2}

1. Brogan, A.P.S, and Hallett, J.P., *Journal of the American Chemical Society*, 2016
2. Brogan, A.P.S, Bui-Le, L., and Hallett, J.P., *Nature Chemistry*, 2018

Nanoscale Liquids



nanoscale
→



- Nanoscale objects do not have a liquid phase.
- Interparticle interactions need to be extended.

Liquid Proteins



The diagram illustrates the assembly of a liquid protein droplet through three steps:

- (1) A protein monomer (blue ribbon) forms a protein core (blue and red spheres).
- (2) The protein core is surrounded by lipid molecules (gray and red spheres).
- (3) The assembly forms a large, dense droplet.


A photograph on the right shows a glass rod with a dark liquid droplet, representing the experimental observation of a liquid protein droplet.


CN(C)CCCCN(C)C

(3) Lyophilization of conjugate, followed by annealing at 60 ° C to form solvent-free liquid protein.




- Retained structure and hyperthermophilic-like stability.
- Biological function in the absence of water.
- Protein dynamics retained within organic corona.







Water




Acetonitrile




- Molecular dynamics simulations from aqueous to solvent-free state (≥ 100 ns).
- Observe surfactant corona behaviour in water and organic solvent.
- Discrete conjugates in solvent-free liquid with some interdigitation.
- Consistent with SANS measurements.




Solvent-free




Protein stability in Ionic Liquids



- UV/Vis shows retention of structure in all conditions
- SRCD indicated ionic liquids induced α -helicity
- Thermal stability of proteins increased significantly in ionic liquid



Ionogels



Ionogel


Hydrogel



24 h



- Relatively new material – come into prominence over past decade.
- Gel system of ionic liquid encapsulated by polymer matrix.
- Current research concentrating on soft electronics – **little to no research on biocatalysis or biointerfacing.**





PEG


[emim][EtSO₄]



[emim][OAc]

[emim][OTf]





- Changing ionic liquids affects properties – modular.
- Mechanical properties dictated by ionic liquid (and polymer content)
- Very stable to temperature – and some stability towards solvents.





- M13 is a filamentous bacteriophage with extremely high aspect ratio – 10 nm wide by 900 nm long.
- Used by Belcher Lab (MIT) as highly versatile scaffold for templating various materials.
- Prospective uses as soft batteries and catalytic materials.

M13 Ionogels




- Possible to make mixtures of M13 biofluid and ionic liquids.
- Structure maintained in the ionic liquids.
- Ionogels with M13 inside can be created.




Binding studies: Antibodies

- **Strongest** non-covalent interaction
- **46 % activity** compared to native after **10 injections**



Streptavidin bound to 2 biotin molecules



Isothermal calorimetry data comparing the heat of binding for the unmodified and modified streptavidin with iminobiotin at pH 9.5

Contacts

- Nanoparticle delivery vehicles
- Freeze dried formulations
 - rongjun.chen@imperial.ac.uk
- Ionic liquids for thermo-stabilisation
 - j.hallett@imperial.ac.uk

Thank you for your attention